Article and Video CATEGORIES

Cancer Journey

Search By

Lesser Known Lung Cancer Mutations Part 2: BRAF inhibitors as another targeted therapy bullseye?
Author
Dr. Pinder

Recently, I described the rationale for targeting HER2 mutations in non-small cell lung cancer (NSCLC). Most of our experience with HER2 targeted therapy comes from studies in breast cancer. Now, I'd like to introduce you to BRAF, another novel target in NSCLC that is a central component in cell signalling, growth, and division.

braf (click on image to enlarge)

Most of our current information about BRAF comes from promising studies conducted with BRAF inhibitors in melanoma, a cancer that has been notoriously difficult to treat. Overall, BRAF mutations are one of the most common mutations in human cancers, though in lung cancer we estimate the frequency of BRAF mutations at only 1-3%. We've known for a while that these mutations occur in NSCLC but interest is really just picking up. Why? First, there are several BRAF inhibitors, some of which are showing promise in BRAF-mutated melanoma. Second, we now have more widespread ability to test for BRAF mutations (thanks to the success in melanoma) and to identify patients for clinical trials of BRAF inhibitors.

BRAF, like EGFR and other proteins involved in cancer progression, is part of a pathway that transmits signals from the cell surface to the interior of cell, ultimately leading to cell proliferation or in the case of cancer, progression. MEK is a protein which is downstream of BRAF and one of the key proteins involved in cellular growth and proliferation. MEK inhibitors represent another group of drugs that may be used to target this pathway. While it is still early in the BRAF story, we have learned some valuable lessons by looking at the tumors of patients with NSCLC. In contrast to melanoma, where only one specific mutation is found (called the V600E), in lung cancer, there are multiple different mutations that can occur in BRAF. This makes testing more complicated and expensive because we have to test for multiple mutations. We also are not sure yet if particular mutations will be more likely to predict response to drugs targeting the BRAF pathway. Although the number of patients studied to date has been small, it appears that BRAF mutations are most likely to occur in adenocarcinomas and in former or current smokers. It also appears that BRAF mutations are not found in patients who have KRAS or EGFR mutations. In laboratory studies, cells with BRAF mutations were resistant to EGFR inhibitors.

So what does this mean for lung cancer patients? In melanoma, BRAF inhibitors are showing great promise. We hope that on a molecular level, BRAF mutant lung cancer will behave like BRAF mutant melanoma and that the chance of response to these drugs will be high. The Lung Cancer Mutation Consortium trial tests for multiple BRAF mutations, and clinical trials of BRAF inhibitors will be offered through the consortium. Testing for the V600E mutation is more widely available and may also identify patients who can then be referred for BRAF inhibitor trials. Interestingly, Nexavar (sorafenib), which inhibits multiple targets, also has activity against BRAF (its name of sorafenib refers to this, actually). This drug has shown some promise in patients with KRAS mutations though this drug has not been investigated specifically in a BRAF-mutant patient population. Currently, the idea is to use BRAF inhibitors drugs in second-line or greater patients so previous treatment with chemotherapy will be required to participate. Side effects described so far have been for the most part mild, primarily consisting of fatigue, headaches, decreased appetite and skin changes. Stay tuned: I hope that we will be able to get a large number of patients tested for BRAF and on these clinical trials.

Next Previous link

Previous PostNext Post

Related Content

Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
HPV Advances
Video
In this video series, Dr. Paul Romesser discusses recent advances in HPV related cancers, including treatment options, vaccination recommendations and patient perspectives.   To watch the full playlist click here.  

Forum Discussions

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Hi Miranda, I hope I can put your mind at ease. The reasons for your symptoms are numerous and a pancoast tumor is close the bottom of that list.  A lot...

Hello CRT, Welcome to GRACE.  I'm so sorry your husband's cancer is figuring out a work around tagrisso.  I'm sorry his onc hasn't been more communicative.  It's pretty standard to stay...

Thank you for your quick reply! What you mention about hospice makes sense.

And thank you for the link regarding other opinions.

My husband recently took a Guardant blood test but...

Recent Comments

JOIN THE CONVERSATION
My first thought is to ask…
By JanineT GRACE … on
Hi CRT, I wanted to share…
By JanineT GRACE … on
Hi and welcome to GRACE.  I…
By JanineT GRACE … on
Update
By APT_CL on